Preventative Effects of 4,4'-Diphenylmethane-bis(methyl) Carbamate Isolated from Cortex Mori on Human Umbilical Vein Endothelial Cell Dysfunction Induced by Advanced Glycation End Products
Corresponding Author
Liang Feng
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Quan Zhu and Liang Feng, Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group No. 71, Dongpeng Road, Eastern District, Economy Technology Development Park, Guangzhou, 510530, China.
E-mail: [email protected]; [email protected]
Search for more papers by this authorYou-hua Xu
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorShan-shan Wang
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorWai Au-yeung
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorZhao-guang Zheng
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Search for more papers by this authorRu-shang Wang
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Search for more papers by this authorCorresponding Author
Quan Zhu
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Quan Zhu and Liang Feng, Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group No. 71, Dongpeng Road, Eastern District, Economy Technology Development Park, Guangzhou, 510530, China.
E-mail: [email protected]; [email protected]
Search for more papers by this authorPing Xiang
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorCorresponding Author
Liang Feng
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Quan Zhu and Liang Feng, Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group No. 71, Dongpeng Road, Eastern District, Economy Technology Development Park, Guangzhou, 510530, China.
E-mail: [email protected]; [email protected]
Search for more papers by this authorYou-hua Xu
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorShan-shan Wang
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorWai Au-yeung
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorZhao-guang Zheng
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Search for more papers by this authorRu-shang Wang
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Search for more papers by this authorCorresponding Author
Quan Zhu
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group, Guangzhou, 510530 China
Quan Zhu and Liang Feng, Institute of Conson Co. for Chinese Medicine in Kidney Diseases, Consun Pharmaceutical Group No. 71, Dongpeng Road, Eastern District, Economy Technology Development Park, Guangzhou, 510530, China.
E-mail: [email protected]; [email protected]
Search for more papers by this authorPing Xiang
State Key Laboratory of Quality Research in Chinese Medicine, Biotechnology Labortory of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau
Search for more papers by this authorAbstract
Advanced glycation end-products (AGEs) have been regarded as an initial motivating factor in the pathogenesis of endothelial dysfunction in diabetic complications. 4,4'-Diphenylmethane-bis(methyl) carbamate (DMPC), a carbamate compound, was isolated from Cortex Mori and its prevention effects against AGEs-induced endothelial dysfunction were studied. 4,4'-Diphenylmethane-bis(methyl) carbamate significantly reduced cell apoptosis to normal level at 10−9 mol/L concentration. Advanced glycation end-products up-regulated the expression of Bad and Bax and down-regulated Bcl-2 proteins, and pretreatment with DMPC significantly down-regulated Bad and Bax while up-regulating Bcl-2 expressions. In addition, ICAM (intercellular adhesion molecule)-1 and TGF (transforming growth factor)-β1 expressions in human umbilical vein endothelial cell (HUVEC) were significantly enhanced by AGEs. More importantly, these increases of ICAM-1 and TGF-β1 expressions were reduced meaningfully with the pretreatment of DMPC. All the results showed DMPC had prevention effects against the progression of AGE-induced endothelial dysfunction, and this compound might be a promising agent against endothelial dysfunction in diabetic vascular complications. Copyright © 2011 John Wiley & Sons, Ltd.
REFERENCES
- Antonsson B, Martinou JC. 2000. The Bcl-2 protein family. Exp Cell Res 256: 50–57.
- Bento CF, Fernandes R, Matafome P, Sena C, Seiça R, Pereira P. 2010. Methylglyoxal-induced imbalance in the ratio of vascular endothelial growth factor to angiopoietin 2 secreted by retinal pigment epithelial cells leads to endothelial dysfunction. Exp Physiol 95: 955–970.
- Bosevski M, Georgievska-Ismail L. 2010. Ultrasound measurement of peripheral endothelial dysfunction in type 2 diabetic patients: correlation with risk factors. Bosn J Basic Med Sci 10: 84–88.
- Busch M, Franke S, Rüster C, Wolf G. 2010. Advanced glycation end-products and the kidney. Eur J Clin Invest 40: 742–755.
- Chen BH, Jiang DY, Tang LS. 2006. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci 79: 1040–1048.
- Csiszar A, Ungvari Z. 2008. Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling. Am J Physiol Heart Circ Physiol 295: H475–H476.
- Gielen S, Erbs S, Schuler G, Hambrecht R. 2002. Exercise training and endothelial dysfunction in coronary artery disease and chronic heart failure. From molecular biology to clinical benefits. Minerva Cardioangiol 50: 95–106.
- Ding H, Triggle CR. 2010. Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Arch 459: 977–994.
- Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458: 509–513.
- Flyvbjerg A, Khatir DS, Jensen LJ, Dagnaes-Hansen F, Gronbaek H, Rasch R. 2004. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr Pharm Des 10: 3385–3394.
- Fröhlich-Reiterer EE, Borkenstein MH. 2010. Microvascular and macrovascular complications in children and adolescents with type 1 diabetes mellitus. Wien Med Wochenschr 160: 414–418.
- Hung YJ, Lee CH, Chu NF, Shieh YS. 2010. Plasma protein growth arrest-specific 6 levels are associated with altered glucose tolerance, inflammation, and endothelial dysfunction. Diabetes Care 33: 1840–1844.
- Ishibashi T, Kawaguchi M, Sugimoto K, Uekita H, Sakamoto N, Yokoyama K, et al. 2010. Advanced glycation end product-mediated matrix metallo-proteinase-9 and apoptosis via renin–angiotensin system in type 2 diabetes. J Atheroscler Thromb 17: 578–589.
- Jenkins AJ, McBride JD, Januszewski AS, et al. 2010. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res 2: 19.
- Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, et al. 1997. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 132: 1263–1270.
- Kwak HB, Song W, Lawler JM. 2006. Exercise training attenuates age-induced elevation in Bax/Bcl-2 ratio, apoptosis, and remodeling in the rat heart. FASEB J 20: 791–793.
- Leite M, Quinta-Costa M, Leite PS, Guimarães JE. 1999. Critical evaluation of techniques to detect and measure cell death--study in a model of UV radiation of the leukaemic cell line HL60. Anal Cell Pathol 19: 139–151.
- Li A, Dubey S, Varney ML, Dave BJ, Singh RK. 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369–3376.
- Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW. 2006. Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 95: 320–328.
- Lu T, Tian L, Han Y, Vogelbaum M, Stark GR. 2007. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci US A 104: 4365–4370.
- Ma L, Gao HQ, Li BY, Ma YB, You BA, Zhang FL. 2007. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma. J Cardiovasc Pharmacol 49: 293–298.
- Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. 2009. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 385: 269–272.
- Mehmeti I, Lenzen S, Lortz S. 2011. Modulation of Bcl-2-related protein expression in pancreatic beta cells by pro-inflammatory cytokines and its dependence on the antioxidative defense status. Mol Cell Endocrinol 332: 88–96.
- Nagase Y, Iwasawa M, Akiyama T, Ogata N, Kadono Y, Nakamura M, et al. 2010. Antiapoptotic molecule Bcl-2 is essential for the anabolic activity of parathyroid hormone in bone. Ann N Y Acad Sci 1192: 330–337.
- Nakamura S, Tachikawa T, Tobita K, Miyazaki S, Sakai S, Morita T, et al. 2003. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 41: S61–S67.
- Nur E, Brandjes DP, Schnog JJ, Otten HM, Fijnvandraat K, Schalkwijk CG, et al. 2010. The CURAMA Study Group. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. Br J Haematol 151: 62–69.
- Pecci A, Scholz A, Pelster D, Beato M. 1997. Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl-XL to bcl-XS. J Biol Chem 272: 1791–11798.
- Piconi L, Corgnali M, Da Ros R, Assaloni R, Piliego T, Ceriello A. 2008. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose. J Diabetes Complications 22: 38–45.
- Rodiño-Janeiro BK, González-Peteiro M, Ucieda-Somoza R, González-Juanatey J, Alvarez E. 2010. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev 26: 550–558.
- Rőszer T. 2011. Inflammation as death or life signal in diabetic fracture healing. Inflamm Res 60: 3–10.
- Shen J, Wu Y, Xu JY, et al. 2010. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci 51: 35–46.
- Sho-ichi Y, Yosuke I, Tamami O, Shinjiro A, Kohachiro K, Masayoshi T, et al. 2002. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277: 20309–20315.
- Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. 2007. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res 32: 533–541.
- Tao Y, Fu Z, Zhang M, Xia G, Yang J, Xie H. 2004. Immunohistochemical localization of inducible and endothelial nitric oxide synthase in porcine ovaries and effects of NO on antrum formation and oocyte meiotic maturation. Mol Cell Endocrinol 222: 93–103.
- Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG. 2010. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 106: 93–101.
- Van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. 2010. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010: 792393.
- Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beelen RJ. 2003. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 23: 213–221.
- Willemsen S, Hartog JW, Hummel YM, et al. 2011. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail 13: 76–82.
- Wong WT, Wong SL, Tian XY, Huang Y. 2010. Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 55: 300–307.
- Xu Y, Wang S, Feng L, Zhu Q, Xiang P, He B. 2010. Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. Int Immunopharmacol 10: 1552–1559.
- Zhang FL, Gao HQ, Wu JM, et al. 2006. Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by advanced glycation end products in endothelial cells. J Cardiovasc Pharmacol 48: 47–53.
- Zhu Q, Shi XH, Tang D, et al. 2010. A Pharmaceutical Composition for Treating Diabetic Nephropathy and the Preparation Method and Use Thereof. WIPO Patent Application WO/2010/081263.
Citing Literature
